TTD | Drug: D0C1LH

Drug General Information
Drug ID	D0C1LH
Former ID	DIB010630
Drug Name	DS-8273
Drug Type	Antibody
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[524661]
Company	Daiichi sankyo
Target and Pathway
Target(s)	D(1B) dopamine receptor	Target Info		[550586]
KEGG Pathway	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Dopaminergic synapse
PANTHER Pathway	Dopamine receptor mediated signaling pathway
Reactome	Dopamine receptors
Reactome	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524661	ClinicalTrials.gov (NCT02076451) Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
Ref 550586	Clinical pipeline report, company report or official report of Daiichi Sankyo.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information